A molecular evaluation of surplus cervical samples found the GynTect DNA methylation assay delivered substantially lower positivity than p16/Ki-67 dual staining in women with abnormal cytology. In the reported cohort of 1,000 women (PAP III or greater), GynTect produced a 27.7% positivity rate versus 88.3% for dual staining. The study suggests the methylation panel is more selective, with positivity increasing monotonically with cytology severity—17.0% in LSIL-equivalent categories and rising to 65.0% in high-grade groups. Within HPV16/18-positive subgroups, dual staining again marked far more cases positive (94.8%) than GynTect (38.4%). For screening programs balancing sensitivity and overtreatment, the comparative performance could inform triage pathways when the goal is to reduce false positives and unnecessary procedures while preserving risk stratification.
Get the Daily Brief